{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T13:37:58Z","timestamp":1790948278785,"version":"4.1.0"},"reference-count":39,"publisher":"American Medical Association (AMA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>The neuroimmune system represents a promising target for novel medications for alcohol use disorder (AUD). Ibudilast is a neuroimmune modulator which selectively inhibits phosphodiesterases (PDE) 3, PDE4, PDE10, and PDE11, and macrophage migration inhibitory factor (MIF).<\/jats:p><\/jats:sec>Objective<\/jats:title>To test the efficacy of ibudilast for AUD compared with placebo.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This randomized clinical trial was a double-masked, phase 2 trial conducted at an academic research center between October 2018 and April 2023. Eligible participants were adults seeking treatment for moderate or severe AUD. After completing the 12-week treatment period, participants were followed up for an additional 4 weeks.<\/jats:p><\/jats:sec>Interventions<\/jats:title>Ibudilast taken twice daily in 50 mg doses for 12 weeks vs placebo.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>Percentage of heavy drinking days; secondary efficacy outcomes included drinks per day, drinks per drinking day, and percentage of days abstinent. Registered exploratory analyses tested whether the effects of ibudilast of drinking outcomes were moderated by baseline depressive symptomatology. Registered exploratory analyses also tested whether ibudilast reduced inflammation compared with placebo, as indicated by circulating levels of proinflammatory markers over the 12-week trial. Additionally, a post hoc exploratory analysis investigated whether sex moderated the effect of ibudilast on drinking outcomes. Data were analyzed between October 2018 and April 2023.<\/jats:p><\/jats:sec>Results<\/jats:title>A total of 102 participants were enrolled in the study (mean [SD] age, 44.3 [10.8] years; 61 male [59.8%]; 24 Black [23.5%], 32 Hispanic [31.4%], 52 White [51.0%]). Baseline demographic characteristics and alcohol use patterns did not significantly differ between the 2 medication conditions. There was no significant difference between ibudilast vs placebo on percentage of heavy drinking days (\u03b2\u2009=\u20090.06, SE\u2009=\u20090.08 [95% CI, \u22120.09 to 0.21]; P<\/jats:italic>\u2009=\u2009.46). There were no significant differences between ibudilast vs placebo on registered secondary outcomes. There were no significant effects of ibudilast compared with placebo on peripheral markers of inflammation. Moderation analyses found that baseline depressive symptomology (time 2 for drinks per drinking day: \u03b2\u2009=\u20090.25, SE\u2009=\u20090.11 [95% CI, 0.03 to 0.48]; P<\/jats:italic>\u2009=\u2009.03) and sex (\u03b2\u2009=\u2009\u22122.48, SE\u2009=\u20091.07 [95% CI, \u22124.59 to \u22120.37]; P<\/jats:italic>\u2009=\u2009.02) may moderate the effects of ibudilast.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>In this randomized clinical trial of ibudilast for the treatment of AUD, there was no support for the efficacy of ibudilast over placebo; additionally, no effect of ibudilast on markers of peripheral inflammation was observed. As novel treatments for AUD are developed for novel molecular targets, their effects may depend on mechanisms and moderators of efficacy.<\/jats:p><\/jats:sec>Trial Registration<\/jats:title>ClinicalTrials.gov Identifier: NCT03594435<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2025.7523","type":"journal-article","created":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T23:30:21Z","timestamp":1746055821000},"page":"e257523","source":"Crossref","is-referenced-by-count":17,"title":["A Neuroimmune Modulator for Alcohol Use Disorder"],"prefix":"10.1001","volume":"8","author":[{"given":"Lara A.","family":"Ray","sequence":"first","affiliation":[{"name":"Department of Psychology, University of California at Los Angeles"},{"name":"Department of Psychiatry and Biobehavioral Sciences, University of California at Los Angeles"},{"name":"Brain Research Institute, University of California at Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsay R.","family":"Meredith","sequence":"additional","affiliation":[{"name":"Department of Psychology, University of California at Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica N.","family":"Grodin","sequence":"additional","affiliation":[{"name":"Department of Psychology, University of California at Los Angeles"},{"name":"Department of Psychiatry and Biobehavioral Sciences, University of California at Los Angeles"},{"name":"Brain Research Institute, University of California at Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malia A.","family":"Belnap","sequence":"additional","affiliation":[{"name":"Department of Psychology, University of California at Los Angeles"},{"name":"Brain Research Institute, University of California at Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven J.","family":"Nieto","sequence":"additional","affiliation":[{"name":"Department of Psychology, University of California at Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wave A.","family":"Baskerville","sequence":"additional","affiliation":[{"name":"Department of Psychology, University of California at Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanna","family":"Donato","sequence":"additional","affiliation":[{"name":"Department of Psychology, University of California at Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven J.","family":"Shoptaw","sequence":"additional","affiliation":[{"name":"Center for Behavioral and Addiction Medicine, Department of Family Medicine, University of California at Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Artha J.","family":"Gillis","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Biobehavioral Sciences, University of California at Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Irwin","sequence":"additional","affiliation":[{"name":"Department of Psychology, University of California at Los Angeles"},{"name":"Department of Psychiatry and Biobehavioral Sciences, University of California at Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Miotto","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Biobehavioral Sciences, University of California at Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig K.","family":"Enders","sequence":"additional","affiliation":[{"name":"Department of Psychology, University of California at Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2025,4,30]]},"reference":[{"issue":"1","key":"zoi250279r1","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1038\/npp.2016.177","article-title":"The neuroimmune basis of excessive alcohol consumption.","volume":"42","author":"Mayfield","year":"2017","journal-title":"Neuropsychopharmacology"},{"key":"zoi250279r2","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/978-3-319-96523-9","article-title":"Innate immune signaling and alcohol use disorders.","volume":"248","author":"Coleman","year":"2018","journal-title":"Handb Exp Pharmacol"},{"issue":"1","key":"zoi250279r3","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s00401-013-1233-3","article-title":"Human alcohol-related neuropathology.","volume":"127","author":"de la Monte","year":"2014","journal-title":"Acta Neuropathol"},{"issue":"9","key":"zoi250279r4","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1007\/s00213-015-3906-1","article-title":"Mechanisms of neuroimmune gene induction in alcoholism.","volume":"233","author":"Crews","year":"2016","journal-title":"Psychopharmacology (Berl)"},{"key":"zoi250279r5","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.pbb.2018.12.007","article-title":"Neuroimmune signaling in alcohol use disorder.","volume":"177","author":"Erickson","year":"2019","journal-title":"Pharmacol Biochem Behav"},{"key":"zoi250279r6","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.pnpbp.2015.06.013","article-title":"The role of the gut-brain axis in alcohol use disorders.","volume":"65","author":"Gorky","year":"2016","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"3","key":"zoi250279r7","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1037\/a0035302","article-title":"From stress to inflammation and major depressive disorder: a social signal transduction theory of depression.","volume":"140","author":"Slavich","year":"2014","journal-title":"Psychol Bull"},{"key":"zoi250279r8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/B978-0-12-801284-0.00001-4","article-title":"Neuroimmune mechanisms of alcohol and drug addiction.","volume":"118","author":"Cui","year":"2014","journal-title":"Int Rev Neurobiol"},{"key":"zoi250279r9","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.bbi.2021.07.023","article-title":"Immune treatments for alcohol use disorder: a translational framework.","volume":"97","author":"Meredith","year":"2021","journal-title":"Brain Behav Immun"},{"issue":"7","key":"zoi250279r10","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1517\/13543784.16.7.935","article-title":"Ibudilast (AV-411). A new class therapeutic candidate for neuropathic pain and opioid withdrawal syndromes.","volume":"16","author":"Ledeboer","year":"2007","journal-title":"Expert Opin Investig Drugs"},{"issue":"3","key":"zoi250279r11","doi-asserted-by":"publisher","first-page":"269","DOI":"10.4155\/cli.14.8","article-title":"Ibudilast for the treatment of drug addiction and other neurological conditions.","volume":"4","author":"Johnson","year":"2014","journal-title":"Clin Investig (Lond)"},{"issue":"5","key":"zoi250279r12","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/S0165-6147(97)01049-3","article-title":"Phosphodiesterase (PDE)4 inhibitors: anti-inflammatory drugs of the future?","volume":"18","author":"Teixeira","year":"1997","journal-title":"Trends Pharmacol Sci"},{"issue":"10","key":"zoi250279r13","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1038\/nri1200","article-title":"Macrophage migration inhibitory factor: a regulator of innate immunity.","volume":"3","author":"Calandra","year":"2003","journal-title":"Nat Rev Immunol"},{"issue":"10","key":"zoi250279r14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0013417","article-title":"Inhibition of the striatal specific phosphodiesterase PDE10A ameliorates striatal and cortical pathology in R6\/2 mouse model of Huntington\u2019s disease.","volume":"5","author":"Giamp\u00e0","year":"2010","journal-title":"PLoS One"},{"issue":"3","key":"zoi250279r15","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.neuropharm.2003.09.009","article-title":"Neuroprotective role of phosphodiesterase inhibitor ibudilast on neuronal cell death induced by activated microglia.","volume":"46","author":"Mizuno","year":"2004","journal-title":"Neuropharmacology"},{"issue":"1","key":"zoi250279r16","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1111\/adb.12106","article-title":"Ibudilast reduces alcohol drinking in multiple animal models of alcohol dependence.","volume":"20","author":"Bell","year":"2015","journal-title":"Addict Biol"},{"issue":"9","key":"zoi250279r17","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1038\/npp.2017.10","article-title":"Development of the neuroimmune modulator ibudilast for the treatment of alcoholism: a randomized, placebo-controlled, human laboratory trial.","volume":"42","author":"Ray","year":"2017","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"zoi250279r18","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1038\/s41398-021-01478-5","article-title":"Ibudilast, a neuroimmune modulator, reduces heavy drinking and alcohol cue-elicited neural activation: a randomized trial.","volume":"11","author":"Grodin","year":"2021","journal-title":"Transl Psychiatry"},{"issue":"3","key":"zoi250279r19","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1007\/s11481-013-9460-x","article-title":"Magnetic resonance spectroscopy to assess neuroinflammation and neuropathic pain.","volume":"8","author":"Chang","year":"2013","journal-title":"J Neuroimmune Pharmacol"},{"issue":"7","key":"zoi250279r20","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1097\/WNR.0000000000001781","article-title":"Magnetic resonance spectroscopy shows associations between neurometabolite levels and perivascular space volume in Parkinson\u2019s disease: a pilot and feasibility study.","volume":"33","author":"Donahue","year":"2022","journal-title":"Neuroreport"},{"issue":"3","key":"zoi250279r21","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1080\/00952990.2022.2124918","article-title":"Baseline C-reactive protein levels are predictive of treatment response to a neuroimmune modulator in individuals with an alcohol use disorder: a preliminary study.","volume":"49","author":"Grodin","year":"2023","journal-title":"Am J Drug Alcohol Abuse"},{"issue":"11","key":"zoi250279r22","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1111\/j.1360-0443.1989.tb00737.x","article-title":"Assessment of alcohol withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar).","volume":"84","author":"Sullivan","year":"1989","journal-title":"Br J Addict"},{"key":"zoi250279r23","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.cct.2016.08.006","article-title":"An exploratory evaluation of Take Control: a novel computer-delivered behavioral platform for placebo-controlled pharmacotherapy trials for alcohol use disorder.","volume":"50","author":"Devine","year":"2016","journal-title":"Contemp Clin Trials"},{"issue":"1","key":"zoi250279r26","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1037\/0022-006X.62.1.75","article-title":"Misuse of statistical test in three decades of psychotherapy research.","volume":"62","author":"Dar","year":"1994","journal-title":"J Consult Clin Psychol"},{"issue":"2","key":"zoi250279r27","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1177\/1536867X0800800212","article-title":"Stata tip 63: Modeling proportions.","volume":"8","author":"Baum","year":"2008","journal-title":"Stata J"},{"issue":"3","key":"zoi250279r29","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1037\/met0000184","article-title":"Quantifying explained variance in multilevel models: an integrative framework for defining R-squared measures.","volume":"24","author":"Rights","year":"2019","journal-title":"Psychol Methods"},{"issue":"1-2","key":"zoi250279r30","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.drugalcdep.2007.08.017","article-title":"Evidence for a closing gender gap in alcohol use, abuse, and dependence in the United States population.","volume":"93","author":"Keyes","year":"2008","journal-title":"Drug Alcohol Depend"},{"issue":"2","key":"zoi250279r31","doi-asserted-by":"publisher","first-page":"01","DOI":"10.35946\/arcr.v40.2.01","article-title":"Gender differences in the epidemiology of alcohol use and related harms in the United States.","volume":"40","author":"White","year":"2020","journal-title":"Alcohol Res"},{"issue":"7","key":"zoi250279r32","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1111\/acer.14082","article-title":"Is there a recent epidemic of women\u2019s drinking? A critical review of national studies.","volume":"43","author":"Keyes","year":"2019","journal-title":"Alcohol Clin Exp Res"},{"issue":"10","key":"zoi250279r33","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1001\/jamapsychiatry.2022.2096","article-title":"Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder: a randomized clinical trial.","volume":"79","author":"Bogenschutz","year":"2022","journal-title":"JAMA Psychiatry"},{"issue":"1","key":"zoi250279r34","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1111\/acer.13917","article-title":"Gabapentin enacarbil extended-release for alcohol use disorder: a randomized, double-blind, placebo-controlled, multisite trial assessing efficacy and safety.","volume":"43","author":"Falk","year":"2019","journal-title":"Alcohol Clin Exp Res"},{"issue":"1","key":"zoi250279r35","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1080\/13543784.2018.1417383","article-title":"Gabapentin for the treatment of alcohol use disorder.","volume":"27","author":"Mason","year":"2018","journal-title":"Expert Opin Investig Drugs"},{"issue":"6","key":"zoi250279r36","doi-asserted-by":"publisher","DOI":"10.1172\/JCI159103","article-title":"Preclinical and clinical evidence for suppression of alcohol intake by apremilast.","volume":"133","author":"Grigsby","year":"2023","journal-title":"J Clin Invest"},{"issue":"4","key":"zoi250279r37","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1038\/npp.2017.282","article-title":"Precision medicine in alcohol dependence: a controlled trial testing pharmacotherapy response among reward and relief drinking phenotypes.","volume":"43","author":"Mann","year":"2018","journal-title":"Neuropsychopharmacology"},{"issue":"5","key":"zoi250279r38","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1001\/jamainternmed.2020.0249","article-title":"Efficacy of gabapentin for the treatment of alcohol use disorder in patients with alcohol withdrawal symptoms: a randomized clinical trial.","volume":"180","author":"Anton","year":"2020","journal-title":"JAMA Intern Med"},{"issue":"13","key":"zoi250279r39","doi-asserted-by":"publisher","first-page":"2250","DOI":"10.1038\/s41386-021-01055-w","article-title":"Efficacy and tolerability of baclofen in a U.S. community population with alcohol use disorder: a dose-response, randomized, controlled trial.","volume":"46","author":"Garbutt","year":"2021","journal-title":"Neuropsychopharmacology"},{"key":"zoi250279r24","volume-title":"Manual for the Beck Depression Inventory-II","author":"Beck","year":"1996"},{"key":"zoi250279r25","doi-asserted-by":"crossref","DOI":"10.1093\/acprof:oso\/9780195152968.001.0001","volume-title":"Applied Longitudinal Data Analysis: Modeling Change and Event Occurrence","author":"Singer","year":"2003"},{"key":"zoi250279r28","volume-title":"Statistical Power Analysis for the Behavioral Sciences","author":"Cohen","year":"1988","edition":"2nd ed"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2833329\/ray_2025_oi_250279_1745261964.26068.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T23:30:23Z","timestamp":1746055823000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2833329"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2025,4,30]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.7523","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,30]]}}}